|
Osteosarcoma
|
0.200 |
Biomarker
|
disease |
HPO |
|
|
|
|
Osteosarcoma
|
0.200 |
Biomarker
|
disease |
BEFREE |
Our data suggest that MDM2 gene amplification may be associated with tumor progression and metastasis in osteosarcoma.
|
8416741 |
1993 |
|
Osteosarcoma
|
0.200 |
Biomarker
|
disease |
BEFREE |
While p53 mutations and MDM2 amplification have been reported to occur in rhabdomyosarcoma and osteogenic sarcoma, the incidence of MDM2 in other pediatric solid tumors is not known.
|
8261417 |
1993 |
|
Osteosarcoma
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
Whereas MDM2 amplification and/or over-expression were found only in two (U2OS and OSA cell lines) of 18 osteosarcomas, one of 20 malignant fibrous histiocytomas (MFHs), and in none of 14 leiomyosarcomas, such alterations were observed in two of two fibrosarcomas, three of six malignant schwannomas, three of 19 liposarcomas, and in the one hemangiopericytoma examined.
|
8064888 |
1994 |
|
Osteosarcoma
|
0.200 |
Biomarker
|
disease |
BEFREE |
Amplification of the MDM2 gene has recently been observed in soft tissue sarcoma and in osteosarcoma.
|
7519048 |
1994 |
|
Osteosarcoma
|
0.200 |
Biomarker
|
disease |
BEFREE |
A two- to threefold increase in the copy number of MDM2 was detected in 7 of 37 samples, 5 of which were osteosarcomas.
|
8781571 |
1996 |
|
Osteosarcoma
|
0.200 |
Biomarker
|
disease |
BEFREE |
This fact has been described recently and its relation with the amplification of the MDM2 gene observed in osteosarcomas is as yet unknown.
|
8780749 |
1996 |
|
Osteosarcoma
|
0.200 |
Biomarker
|
disease |
BEFREE |
Alterations of the p53/MDM2 pathway are frequent in OS and usually represent mutually exclusive tumorigenic events. p53 does not appear to be a major determinant of proliferative rate in OS.
|
9118036 |
1997 |
|
Osteosarcoma
|
0.200 |
AlteredExpression
|
disease |
BEFREE |
Two follicular lymphomas, three leukaemias, both hepatocellular carcinomas, and the osteosarcoma sample showed transcription of the activated MDM2 gene.
|
9227342 |
1997 |
|
Osteosarcoma
|
0.200 |
Biomarker
|
disease |
BEFREE |
Molecular alterations of the RB1, TP53, and MDM2 genes in primary and xenografted human osteosarcomas.
|
9559293 |
1997 |
|
Osteosarcoma
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
Southern blotting and polymerase chain reaction/single strand conformation polymorphism (PCR-SSCP) analyses were performed to search for MDM2, ras family and p53 gene alterations in 17 patients with high-grade osteosarcomas.
|
9793960 |
1998 |
|
Osteosarcoma
|
0.200 |
Biomarker
|
disease |
BEFREE |
Amplification of the CDK4 gene without MDM2 amplification was observed in osteosarcomas and a chondrosarcoma but not in soft tissue tumors, whereas amplification of MDM2 gene alone was observed in malignant fibrous histiocytomas (MFHs), liposarcomas, and lipomas, but not in bone tumors.
|
9703873 |
1998 |
|
Osteosarcoma
|
0.200 |
Biomarker
|
disease |
BEFREE |
Analysis of SAS gene and CDK4 and MDM2 proteins in low-grade osteosarcoma.
|
10101594 |
1999 |
|
Osteosarcoma
|
0.200 |
Biomarker
|
disease |
BEFREE |
The different patterns of gene amplification and overexpression of CDK4, SAS and MDM2 in parosteal and intramedullary osteosarcomas may help explain the disparity in the biological behaviour of these two types of osteosarcoma.
|
9989829 |
1999 |
|
Osteosarcoma
|
0.200 |
Biomarker
|
disease |
BEFREE |
Strong and uniform CDK4 and MDM2 immunoreactivity was found respectively in three of three and two of three dedifferentiated parosteal osteosarcomas.
|
10943202 |
2000 |
|
Osteosarcoma
|
0.200 |
Biomarker
|
disease |
BEFREE |
Analysis of the p16INK4, p14ARF, p15, TP53, and MDM2 genes and their prognostic implications in osteosarcoma and Ewing sarcoma.
|
10942797 |
2000 |
|
Osteosarcoma
|
0.200 |
AlteredExpression
|
disease |
BEFREE |
To determine the frequency of alterations in these genes and their correlation with clinicopathologic features, we analyzed the MDM2 and CDK4 protein levels by immunohistochemistry and assessed MDM2, CDK4 and SAS amplification by real-time PCR in nine osteosarcomas of the jaws.
|
11564577 |
2001 |
|
Osteosarcoma
|
0.200 |
AlteredExpression
|
disease |
BEFREE |
Our results revealed an inactive form of p53 sporadically seen in the samples, a total loss of Rb protein expression, an increased expression of Cdk4, MDM2, c-fos, and c-myc proteins which literature currently reports being the principal alterations found in osteosarcoma.
|
11115584 |
2001 |
|
Osteosarcoma
|
0.200 |
Biomarker
|
disease |
BEFREE |
Amplification of MDM2 was detected in all five low-grade and four high-grade osteosarcomas, all of which showed ring chromosomes.
|
11793439 |
2002 |
|
Osteosarcoma
|
0.200 |
AlteredExpression
|
disease |
BEFREE |
MDM2 alteration and p21WAF1 expression were not observed in any of the cases of MFH-like OS.
|
12181274 |
2002 |
|
Osteosarcoma
|
0.200 |
AlteredExpression
|
disease |
BEFREE |
We present detailed analysis of TP53 mutations and MDM2 and COPS3 expression levels in a set of 23 OS.
|
12917637 |
2003 |
|
Osteosarcoma
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
These results demonstrate that the inactivation of p53 in osteosarcomas directly by mutation versus indirectly by HDM2 amplification may have different cellular consequences with respect to the stability of the genome.
|
12972634 |
2003 |
|
Osteosarcoma
|
0.200 |
AlteredExpression
|
disease |
BEFREE |
MDM2 alterations and p21WAF1 expression might be involved in the tumorigenesis of low-grade central osteosarcomas.
|
15310147 |
2004 |
|
Osteosarcoma
|
0.200 |
AlteredExpression
|
disease |
BEFREE |
We found that adenovirus-wt p53 (Ad-wt p53) induces significant apoptosis in HT1080 fibrosarcoma cells expressing low levels of Mdm2, but fails to induce apoptosis in SJSA osteosarcoma cells expressing high levels of Mdm2.
|
15026814 |
2004 |
|
Osteosarcoma
|
0.200 |
AlteredExpression
|
disease |
BEFREE |
The hdm-2 oncogene is overexpressed in several types of malignancies including osteosarcomas, soft tissue sarcomas and gliomas and hdm-2 has been associated with accelerated tumor formation in both hereditary and sporadic cancers.
|
16732328 |
2006 |